BioSpace News Archive

Kraig Biocraft Laboratories, Inc., the biotechnology company focused on the development and commercialization of spider silk, announced its continued investment into building its world-class team with the addition of leading sericulture consultants from India.

Krystal Biotech, Inc. today announced that the Company’s Marketing Authorization Application (MAA) to the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for VYJUVEK (beremagene geperpavec-svdt, also known as B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB) has been validated and is now under CHMP review.

AbbVie (NYSE: ABBV) today announced updates from the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for epcoritamab, an investigational T-cell engaging bispecific antibody administered subcutaneously, for relapsed or refractory (R/R) follicular lymphoma (FL).

Genmab Announces Positive Regulatory Updates for Epcoritamab (EPKINLY ® /TEPKINLY ® ) for the Treatment of Relapsed/Refractory Follicular Lymphoma.

TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the 6th Annual Evercore ISI HealthCONx Conference, being held at the Kimpton EPIC Hotel, in Miami, Florida on November 28 - 30, 2023.

Royal Philips, a global leader in health technology, placed workflow and efficiency at the heart of the next generation of its flagship ultrasound systems EPIQ Elite and Affiniti at #RSNA23.

Vor Bio today announced that it will participate in a fireside chat and host virtual 1x1 investor meetings at the JMP Securities Hematology and Oncology Summit.

Cocrystal Pharma, Inc. announces that James Martin, Chief Financial Officer and Co-Chief Executive Officer, will present a Company overview at Noble Capital Markets’ 19th Annual Emerging Growth Equity Conference on Monday, December 4 at 1:30 p.m. Eastern time.

Outlook Therapeutics, Inc. announced the receipt of the official minutes from the Type A meeting with the U.S. Food and Drug Administration held in October 2023 regarding the Complete Response Letter dated August 29, 2023 for the Biologics License Application for ONS-5010, an investigational ophthalmic formulation of bevacizumab under development to treat wet AMD.

Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.